Evidence map›Paper›PMID 37664371›Full record

ArticleCureus2023

Efficacy and Tolerability Evaluation of a Nutraceutical Composition Containing Vitex agnus-castus Extract (EVX40™), Pyridoxine, and Magnesium in Premenstrual Syndrome: A Real-World, Interventional, Comparative Study.

Varun P Sureja, Dharmeshkumar B Kheni, Vishal P Dubey, Jignesh Kansagra, Zeel K Soni, Sandipkumar P Bhatt, Akash Mathuria, Shrikalp S Deshpande

Open access · diamondAbstract read
In one paragraph

Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Varun P SurejaDepartment of Scientific and Medical Affairs, Sundyota Numandis Probioceuticals Pvt. Ltd., Ahmedabad, IND.
Dharmeshkumar B KheniDepartment of Scientific and Medical Affairs, Sundyota Numandis Probioceuticals Pvt. Ltd., Ahmedabad, IND.
Vishal P DubeyDepartment of Scientific and Medical Affairs, Sundyota Numandis Probioceuticals Pvt. Ltd., Ahmedabad, IND.
Jignesh KansagraDepartment of Scientific and Medical Affairs, Sundyota Numandis Probioceuticals Pvt. Ltd., Ahmedabad, IND.
Zeel K SoniDepartment of Pharmacy Practice, K.B. Institute of Pharmaceutical Education and Research, Gandhinagar, IND.
Sandipkumar P BhattDepartment of Pharmacology, K.B. Institute of Pharmaceutical Education and Research, Gandhinagar, IND.
Akash MathuriaDepartment of Pharmacology, K.B. Institute of Pharmaceutical Education and Research, Gandhinagar, IND.
Shrikalp S DeshpandeDepartment of Pharmacology, K.B. Institute of Pharmaceutical Education and Research, Gandhinagar, IND.
National Institute of Pharmaceutical Education and Research · INSun Chemical (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Pre-menstrual syndrome (PMS) is a condition associated with altered hormone levels during the menstrual phase of females and is characterised by physical, emotional, and behavioural symptoms that have a negative impact on the quality of life of females. The symptoms of PMS may vary between individuals, but the major complication is pain, especially during menstrual days. The current treatment strategy involves the use of hormonal therapies and analgesics for symptomatic relief, but these therapies have a risk of potential side effects. The use of herbal and nutraceutical supplements in PMS conditions is increasing due to their long-term safety and proven efficacy. The current real-world study aimed to evaluate the efficacy and tolerability of Ezedayz

Indexed as

ezedayz®magnesiummenstrual painpremenstrual syndromepyridoxinequality of lifevitamin b6vitex agnus castus

Identifiers

PMID37664371
PMCPMC10472015
OpenAlexW4385495964

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.